Response to Suissa and Azoulay. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366

Affiliations

¹ Department of Oncology, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada louise.bordeleau@jcc.hhsc.ca.
² Department of Medicine, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada.

Comment

Louise Bordeleau et al. Diabetes Care. 2014 Oct.

. 2014 Oct;37(10):e217.

doi: 10.2337/dc14-1220.

¹ Department of Oncology, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada louise.bordeleau@jcc.hhsc.ca.
² Department of Medicine, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada.

No abstract available

Comment on

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang Yu P, Ryden LE, Pirags V, Spinas GA, Birkeland KI, Ratner RE, Marin-Neto JA, Keltai M, Riddle MC, Bosch J, Yusuf S, Gerstein HC; ORIGIN Trial Investigators. Bordeleau L, et al. Diabetes Care. 2014;37(5):1360-6. doi: 10.2337/dc13-1468. Epub 2014 Feb 26. Diabetes Care. 2014. PMID: 24574355 Clinical Trial.
Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366.
Suissa S, Azoulay L. Suissa S, et al. Diabetes Care. 2014 Oct;37(10):e216. doi: 10.2337/dc14-1075. Diabetes Care. 2014. PMID: 25249678 No abstract available.